The Endothelial Dysfunction and Pyroptosis Driving the SARS-CoV-2 Immune-Thrombosis

INTRODUCTION

The outbreak of the disease (COVID-19) caused by the new coronavirus (SARS-CoV-2) was declared on January 30, 2020, by the World Health Organization (WHO) a Public Health Emergency of International Importance - the Organization’s highest alert level,^1,2 and since then, the numbers of patients requiring intensive care treatment have been continuously increasing.

Following the injury in type 1 and 2 pneumocytes triggered by SARS-CoV-2 lung infection, an exponential release of inflammatory cytokines (cytokine storm), might be responsible for the alveolar-capillary endothelial activation. However, the endothelial cells also express ACE-2 type receptors,³ thus alveolar-capillary endothelial activations may be exacerbated by the SARS-CoV-2 infection, after the damage of the alveolar epithelial barrier by viral injury.⁴

The lung capillary endothelium, acting as the quiescent barrier and gas exchange alveolar-capillary membrane, may switch after its activation to responsive inflammatory phenotype, expressing cytokines and vascular adhesion molecules that aggravate the cytokines storm,⁵ and may lead to the immuno-thrombotic phenomena.⁶

The peculiar endothelial activation induced by SARS-CoV-2 differs from the other pandemic respiratory disease, such as H1N1pdm09 (caused by Influenza A virus H1N1 subtype) and could link the diffuse alveolar damage (DAD) with the severe systemic immune-thrombosis phenomenon caused by COVID-19. In addition to COVID-19 endothelial activation, the probable higher significant involvement of pyroptosis, in this pandemic disease, but not in H1N1pdm09, may drive the massive endothelial cell death contributing to thrombogenic mechanism.^7,8

The hypothesis of this article is that, different from the H1N1pdm09 disease, the SARS-CoV-2 endothelial activation, followed by pyroptosis, may increase the pro-inflammatory stimuli leading COVID-19 pneumonia to a severe systemic disease that may impair the efforts of the clinical staff to prevent fatal outcomes. Viewed from the intensive care perspective, one aim is to avoid COVID-19 systemic vascular injury as a way to prevent the almost always lethal immune-thrombotic phenomena.

This study aimed to analyze endothelial activation and pyroptosis tissue biomarkers in patients who died with COVID-19 compared with cases of H1N1pdm09 and controls.

METHODS

RESULTS

The baseline characteristic of COVID-19 patients is presented in table 1. The lung samples immunohistochemical results in all groups can be observed in table 1 and figure 1. When comparing COVID-19 group with H1N1 group IL-6 (p=0.0652), TNF-alpha (p=0.0092), ICAM-1 and Caspase-1 (p=0.0009) presenting higher lung tissue expression (Figure 1). The same pattern can be observed when comparing COVID-19 with Control groups (Table 1). The immunohistochemical results of myocardial post-mortem biopsies/necropsy are resumed in table 1.

• Download figure
• Open in new tab

The COVID-19 group presented type 2 pneumocyte hyperplasia associated with hyaline membranes and mild septal thickness with lymphocytic infiltration and edema characterizing proliferative DAD. There are scarce septal and intra-alveolar neutrophils recruitment. It was observed numerous small fibrinous thrombi in small and medium pulmonary arteries following by neutrophilic endotheliitis and endothelial cell tumefaction. Signs of secondary bacterial pneumonia were not observed. However, the histopathological features of H1N1 DAD presented fewer hyaline membranes, but higher septal thickness, with massive septal lymphocytic infiltration and intra-alveolar neutrophils recruitment. There was no significant endothelial activation, fibrinous thrombi, and neutrophilic endotheliitis in H1N1 cases. Signs of bacterial coinfections were found in 8 cases.

The COVID-19 myocardial samples presented significant endothelial activation with endothelial cell tumefaction. There was severe intercellular edema surrounding each of the cardiomyocytes of COVID-19 patients, responsible for spacing the myocardial fibers. Lipofuscin pigment and mild signs of myocardial hyperplasia were present in almost all of cardiomyocytes in both control and COVID-19 patients (data not shown).

DISCUSSION

This study aimed to understand the context of the endothelial activation and pyroptosis in patients that died, after hospitalization, with COVID-19, as these aspects may have a possible influence on subsequent thrombogenic events.

Endothelial activation refers to the inability of the endothelium to regulate vascular homeostasis and mainly describes its imbalance in favor of the pro-inflammatory and prothrombotic effects.¹¹ Infection by SARS-CoV-2 would contribute to endothelial dysfunction and to the peculiar endothelial cell death called pyroptosis.¹² Thus, these two events could also trigger the subsequent immuno-thrombotic process that could have a significant impact on the mortality observed in COVID-19 patients.

The endothelium, without this activation process, provides the suitable luminal surface that does not promote the intrinsic coagulation cascade activation or platelet adhesion, but anticoagulant and fibrinolytic mechanisms.¹³ Faced with the aggression of alveolar epithelial cells by SARS-CoV-2, the capillary-alveolar endothelial cells receive a rain of cytokines (IL-1, IL-6, TNF-alpha) promoting its activation and inducing ICAM-1 via the Nuclear factor-kappa-B (NFκB) pathway.^14-16 Thus, under these inflammatory conditions, a subset of leukocytes (polymorphonuclear leukocytes, macrophages, and mast cells) degranulate enzymes that can contribute to the breakdown of the glycocalyx of endothelial cells.^17,18 The intact glycocalyx serves as a barrier against the platelets and leukocytes and the impairment of its function would lead to the endotheliitis and thrombotic events.^19-23

The macrophages score (CD163+ cells) in the COVID-19 group could amplify the local pro-inflammatory involvement by an earlier recruit of the complement system. Following this pro-inflammatory pattern, the higher and continuous tissue expression of IL-6 and TNF-alpha in the COVID-19 group compared to H1N1 and Control groups (p=0.0652 and p=0.0049; p=0.0092 and p=0.0048 respectively) demonstrate that inflammatory stimulation may be kept active throughout the disease process. It is known that the cytokine profile of patients with SARS showed a marked increase of interferon-gamma, IL-1, IL-6, and IL-12, by at least two weeks after the onset of the disease.^24,25,26

Comparing the COVID-19 with H1N1 or Control groups, the ICAM-1 tissue expression was significantly higher in the former (p=0.0034). An essential consequence of endothelial activation is the expression of adhesion molecules such the ICAM family. These molecules have the classic function of attracting leukocytes to the infected region and have the ability to transmit intracellular signals leading and keeping the pro-inflammatory status, thus perpetuating the innate immune response and subsequent promoting systemic activation of endothelial cells.^27,28 The continuous pro-inflammatory condition would result not only in the dysfunctional endothelium but also lead to the loss of its integrity by endothelial cells death.²⁹ The persistent inflammatory signaling of these adhesion molecules would also contribute to later thrombogenic effects. Patients 5 and 6 (respectively 23 and 38 days of survival) were those with the highest vascular tissue expression of ICAM-1, and this fact could be associated with severe thrombotic events that were seen in these cases.

The relationship between endothelial activation/dysfunction and subsequent thrombotic events is already well-known in cardiovascular diseases³⁰ and diabetes.^31,32 Five of our cases had already comorbidities (data not shown), such systemic arterial hypertension, dyslipidemia, diabetes, chronic kidney disease, and signs of chronic arterial disease. Thus, the permanent status of endothelial activation promoted by these comorbidities would aggravate endothelial dysfunction caused by viral inflammatory response and could be responsible for the most prevalent fatal outcome describe in these patients.³³ Suo et al.³⁴ showed that influenza A H1N1 virus is responsible for potentiating endothelial cell apoptosis in patients who already have atherosclerosis.

In this context, SARS-CoV-2 pneumocytes infection, besides, to have an essential role in inflammatory activation/dysfunction of endothelial cells, it also would lead to endothelial cell death, causing the discontinuity of the alveolar-capillary barrier, facilitating the virus to move from alveolar septum through the alveolar-capillary lumen. Thus, the endothelial cells already devoid of glycocalyx become a target for SARS-CoV-2 by ACE-2 binding, aggravating the endothelial damage.

It has been proposed that pyroptosis could contribute to the death of endothelial cells after SARS-CoV-2 infection.³⁵ Pyroptosis is an inflammatory form of programmed cell death.³⁶ A group of researchers found that SARS-CoV viral proteins can trigger the mechanism of cellular pyroptosis³⁷ and in another study, Middle East respiratory syndrome coronavirus (MERS-CoV) infected macrophages promote high pyroptotic biomarker expressions.³⁸

The virus surface can hold a highly conserved molecular structure that can be recognized by the endothelial cells NOD-like receptors protein 3 (NLRP3). A multiprotein complex (Inflammasome) would form by the binding of the NLRP3, and Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and procaspase-1^39,40 would activate. This structure would result in the activation caspases-1 that would promote the maturation of pro-IL-1B, and pro-IL-18.⁴¹ Gasdermin-D is another target of the proteolytic action of caspases-1^40-42, and the resulting fragments are oligomerized creating a perforation in the plasma membrane.⁴³ Given this, in the final phase of this prosses occurs the release of IL-1B and IL-18, cell edema and consequent cell disruption and death called pyroptosis. The fragmentation resulting from pyroptosis would prevent the replication of pathogens^44-46, and the interleukin release would alert the immune system.

Our results show higher endothelial tissue expressions of Caspase-1 in the COVID-19 group than the H1N1 and Control groups (p=0.0009), suggesting the endothelial cell pyroptosis process promoting by SARS-CoV-2 endothelial infection.

The presence of the same pattern of tissue expression (COVID-19 patients with higher CD163, IL-6, ICAM-1, TNF-alpha, and Caspase-1 tissue expression than control patient) in the myocardial samples might suggest that endothelial dysfunction and pyroptosis mechanism could be more than a local lung process, but a systemic event.

It is known that thrombogenic conditions are quite characteristic in COVID-19³ patients, and the presence of the endothelial dysfunction leads to considering the SARS-CoV-2 infection as a systemic disease triggered by the immuno-thrombotic response. Understanding the complex of events that can be part of immune-thrombosis mechanism might help the health professional to early identify patients with the potential of endothelial activation/dysfunction based on predisposing comorbidities and systemic biomarkers such D-dimer and Angiopoietin-2.⁴⁷ The early diagnosis of endothelial dysfunction could guide health professionals in implementing therapeutic anticoagulation, mitigating thrombogenic events, systemic inflammatory response syndrome (SIRS) and multiple organ failure. It also might be relevant to use pharmacological strategy focusing on endothelial stabilization in patients who already had some chronic type of endothelial activation such as chronic renal disease, diabetes, and hypertension. In conclusion, our findings lead us to suggest the involvement of endothelial activation processes and pyroptosis in a COVID-19. Both processes could be contributing to an immuno-thrombotic response in these patients. This immune-thrombosis event may have devastating clinical consequences with fatal outcome. The study’s main limitations are the small number of cases (n=6)⁴ and data based on FFPE post-mortem samples that can only provide a piece of static information at the time of the death and cannot reconstruct the evolving disease process.